QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
QQQ   444.44 (-0.09%)
AAPL   171.18 (-1.23%)
MSFT   420.89 (-0.13%)
META   490.07 (-0.77%)
GOOGL   150.72 (-0.10%)
AMZN   180.87 (+0.58%)
TSLA   176.83 (-1.67%)
NVDA   903.04 (+0.06%)
NIO   4.66 (-0.21%)
AMD   181.65 (+1.15%)
BABA   72.32 (+1.02%)
T   17.57 (+0.11%)
F   13.20 (+1.07%)
MU   118.04 (-0.92%)
CGC   9.28 (-2.83%)
GE   176.19 (-2.18%)
DIS   122.70 (+1.42%)
AMC   3.84 (-11.52%)
PFE   27.83 (+0.18%)
PYPL   66.75 (+0.27%)
XOM   115.39 (+0.37%)
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

$22.74
+0.04 (+0.18%)
(As of 10:13 AM ET)
Today's Range
$22.26
$22.75
50-Day Range
$17.60
$24.23
52-Week Range
$5.63
$26.35
Volume
17,140 shs
Average Volume
236,296 shs
Market Capitalization
$2.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

NewAmsterdam Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.6% Upside
$31.00 Price Target
Short Interest
Healthy
0.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of NewAmsterdam Pharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$4.10 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.58 out of 5 stars

Medical Sector

260th out of 939 stocks

Pharmaceutical Preparations Industry

114th out of 430 stocks

NAMS stock logo

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NAMS Stock Price History

NAMS Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up to $22.45
NAMS NewAmsterdam Pharma Company N.V.
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
NewAmsterdam Pharma prices $175M share offering
See More Headlines
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NAMS
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$37.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+36.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.09 million
Book Value
$3.50 per share

Miscellaneous

Free Float
87,035,000
Market Cap
$2.03 billion
Optionable
Not Optionable
Beta
0.02
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Michael Harvey Davidson FACC (Age 68)
    Facp., M.D., CEO, President, Executive Board Member & Director
    Comp: $882k
  • Dr. Johannes Jacob Pieter Kastelein FESC (Age 70)
    M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director
    Comp: $677.76k
  • Mr. Mayur Amrat Somaiya (Age 51)
    Chief Financial Officer
    Comp: $130.58k
  • Mr. Douglas F. Kling (Age 51)
    Chief Operating Officer
  • Mr. Jim Jacobson
    Chief Legal Officer & Secretary
  • Dr. Marc Ditmarsch M.D. (Age 57)
    Chief Development Officer
  • Dr. Sheng Cui Ph.D.
    VP & Head of Chemistry Manufacturing and Controls (CMC)
  • Ms. Annie Neild
    VP & Head of Regulatory Affairs
  • Mr. William Jones Jr. (Age 60)
    M.B.A., Chief Commercial Officer

NAMS Stock Analysis - Frequently Asked Questions

Should I buy or sell NewAmsterdam Pharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NAMS shares.
View NAMS analyst ratings
or view top-rated stocks.

What is NewAmsterdam Pharma's stock price target for 2024?

6 Wall Street research analysts have issued 1-year target prices for NewAmsterdam Pharma's shares. Their NAMS share price targets range from $22.00 to $37.00. On average, they anticipate the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 36.6% from the stock's current price.
View analysts price targets for NAMS
or view top-rated stocks among Wall Street analysts.

How have NAMS shares performed in 2024?

NewAmsterdam Pharma's stock was trading at $11.17 at the beginning of the year. Since then, NAMS stock has increased by 103.2% and is now trading at $22.70.
View the best growth stocks for 2024 here
.

When is NewAmsterdam Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our NAMS earnings forecast
.

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fcpm Iii Services B.V. (14.37%), Goldman Sachs Group Inc. (1.68%), Goldman Sachs Group Inc. (1.70%), Parkman Healthcare Partners LLC (0.37%), Opaleye Management Inc. (0.33%) and Citadel Advisors LLC (0.03%). Insiders that own company stock include Johannes Jacob Piete Kastelein and Louis G Lange.
View institutional ownership trends
.

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAMS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners